The IFNG6 composite score, which reflects overall immune activity and predicts response to anti-PD-1 (pembrolizumanb) treatment in cancer patients, was calculated on the basis of the genes reported by Seiwert et al. [24] IFNG6 score was significantly lower in the ARID1A-low group than in the ARID1A-high group (p = 0.01; Figure 7A). Here, PDCD1 is linked to cancer.